Bioceres Crop Solutions Reports Fiscal First Quarter 2027 Financial and Operational Results
Total revenues were $53.8 million in 1Q27. Net loss was $10.8 million and Adjusted EBITDA was $5.3 million.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX), a company focused on developing and commercialising agricultural productivity solutions designed to regenerate farming ecosystems and improve crop resilience to climate change, announced its financial and operational results for the first quarter of fiscal year 2027, ended September 30, 2026.
All financial figures are presented in US dollars and follow International Financial Reporting Standards (IFRS). Year-over-year comparisons are used throughout unless otherwise specified.
Presentation of Results
In January 2026, Bioceres’ Pro Farm Group (PFG) business underwent a foreclosure auction. For accounting purposes, PFG has been classified as discontinued operations, with its assets valued at $15 million, corresponding to the amount awarded to an entity associated with a noteholder.
The company continues to challenge the acceleration of the relevant notes and the foreclosure process through ongoing legal proceedings.
On October 21, 2026, a court allowed the company’s claim concerning potential violations of Article 9 of the New York Uniform Commercial Code and the commercial reasonableness of the foreclosure process to proceed to the discovery stage.
Unless otherwise specified, the financial results presented in this announcement relate to continuing operations. Previous-year figures have also been adjusted to exclude the PFG business.
Financial and Business Highlights
- Total revenue reached $53.8 million, representing a 22% year-over-year decline.
- Gross profit decreased 39% to $18.8 million, with gross margin declining to 35%.
- Selling, General and Administrative (SG&A) expenses remained broadly stable at $17.4 million.
- Net loss from continuing operations increased to $10.8 million compared with $4.7 million in 1Q26.
- Adjusted EBITDA was $5.3 million, compared with $13.9 million in the previous year’s quarter.
- Adjusted EBITDA improved sequentially for the second consecutive quarter.
Management Review
Federico Trucco
Chief Executive Officer, Bioceres Crop Solutions
Key Financial Metrics
Table 1: First Quarter 2027 Financial Performance
Figures in millions of US dollars, except percentages.
| Financial Metric | 1Q26 | 1Q27 | Change |
|---|---|---|---|
| Crop Protection Revenue | 33.2 | 29.1 | -12% |
| Seed and Integrated Products | 12.5 | 5.9 | -53% |
| Crop Nutrition Revenue | 23.4 | 18.8 | -20% |
| Total Revenue | 69.1 | 53.8 | -22% |
| Gross Profit | 30.8 | 18.8 | -39% |
| Gross Margin | 44.5% | 35.0% | -955 bps |
| Net Loss | (4.7) | (10.8) | -127% |
| Adjusted EBITDA | 13.9 | 5.3 | -62% |
Fiscal First Quarter 2027 Financial Results
1. Revenues by Business Segment
Revenue for the first quarter totalled $53.8 million, down from $69.1 million in the corresponding period last year. The decline reflected changes in commercial activity across the company’s soybean-related portfolio and stronger competition in Argentina, where growers became more price-sensitive towards differentiated agricultural inputs.
| Business Segment | 1Q26 ($M) | 1Q27 ($M) | Change |
|---|---|---|---|
| Crop Protection | 33.2 | 29.1 | -12% |
| Seed and Integrated Products | 12.5 | 5.9 | -53% |
| Crop Nutrition | 23.4 | 18.8 | -20% |
| Total Revenue | 69.1 | 53.8 | -22% |
Crop Protection: Revenue declined 12% to $29.1 million, mainly because of lower adjuvant sales.
Seed and Integrated Products: Revenue decreased 53% to $5.9 million. The decline reflected the discontinuation of seed sales, lower seed-treatment package volumes and a shift in some soybean-related purchases into the second quarter.
Crop Nutrition: Revenue declined 20% to $18.8 million, primarily due to lower sales of microbeaded fertilisers and inoculants.
2. Gross Profit and Margin
Gross profit decreased 39% to $18.8 million from $30.8 million in 1Q26. Gross margin declined from 44.5% to 35%, primarily due to lower sales volumes and an unfavourable revenue mix.
A greater contribution from lower-margin raw material sales to Synertech, the company’s microbeaded fertiliser manufacturing joint venture, also affected consolidated margins.
| Business Segment | 1Q26 ($M) | 1Q27 ($M) | Change |
|---|---|---|---|
| Crop Protection | 13.6 | 8.1 | -40% |
| Seed and Integrated Products | 7.6 | 4.2 | -44% |
| Crop Nutrition | 9.6 | 6.4 | -33% |
| Total Gross Profit | 30.8 | 18.8 | -39% |
| Gross Margin | 44.5% | 35.0% | -955 bps |
Crop Protection gross profit decreased 40% to $8.1 million, with margins declining from 41% to 28%. Lower sales of higher-margin adjuvants and a greater contribution from lower-margin products influenced performance.
Seed and Integrated Products gross profit declined 44% to $4.2 million. However, its gross margin improved by approximately 11 percentage points following the discontinuation of lower-margin seed sales.
Crop Nutrition gross profit decreased 33% to $6.4 million. Lower microbeaded fertiliser and inoculant volumes, together with a reduced contribution from higher-margin inoculant revenues, affected segment performance.
3. Operating Expenses
Selling, General and Administrative expenses were $17.4 million in 1Q27, compared with $17.2 million in 1Q26. The company maintained cost discipline despite inflationary pressures in its predominantly Argentine peso-denominated cost base, particularly freight and transportation expenses.
Depreciation and amortisation, share-based incentives and transactional expenses together amounted to $2.1 million, compared with $2.0 million in the prior-year quarter.
Research and Development
Total research and development expenditure was $1.8 million in 1Q27, compared with $3.7 million in 1Q26. Depreciation and amortisation included in R&D expenses amounted to $1.1 million, compared with $1.2 million in the previous year.
4. Net Loss and Adjusted EBITDA
The net loss from continuing operations reached $10.8 million in 1Q27, compared with $4.7 million in the corresponding period last year. The wider loss was primarily associated with lower gross profit, partially offset by lower operating expenses and improved financial results.
Adjusted EBITDA was $5.3 million, down from $13.9 million in 1Q26. Nevertheless, the company recorded sequential improvement for the second consecutive quarter.
| Period | Adjusted EBITDA ($M) |
|---|---|
| 3Q26 | (0.6) |
| 4Q26 | 0.6 |
| 1Q27 | 5.3 |
5. Financial Income and Loss
Net financial results were negative $10.4 million in 1Q27, compared with negative $11.9 million in the prior-year quarter.
| Financial Item | 1Q26 ($M) | 1Q27 ($M) |
|---|---|---|
| Interest Expenses | (7.6) | (10.0) |
| Financial Commissions | (0.6) | (0.4) |
| Fair Value, FX and Other Financial Results | (3.8) | 0.1 |
| Net Financial Result | (11.9) | (10.4) |
The improvement was mainly associated with a smaller negative impact from foreign exchange, fair-value changes and other financial items. This was partly offset by higher interest expenses related to secured notes and the renegotiation of local debt obligations.
Balance Sheet Highlights
Table 5: Capitalisation and Debt
Figures in millions of US dollars.
| Financial Item | September 30, 2025 | September 30, 2026 |
|---|---|---|
| Secured Notes | 103.6 | 112.0 |
| Short-Term Borrowings | 85.1 | 56.1 |
| Long-Term Borrowings | 53.8 | 53.6 |
| Cash and Cash Equivalents | (15.5) | (7.5) |
| Other Short-Term Investments | (1.1) | (1.2) |
| Net Financial Debt | 225.9 | 213.0 |
Total financial debt stood at $221.7 million on September 30, 2026, slightly below the preceding quarter. Cash, cash equivalents and other short-term investments amounted to $8.7 million, resulting in net financial debt of $213 million.
This compared with net financial debt of $225.9 million in September 2025 and $217 million in June 2026.
Following the noteholder acceleration notices, approximately $112 million in secured notes remained classified as short-term debt. The company continues to dispute the acceleration and foreclosure proceedings.
Unaudited Consolidated Financial Statements
Table 6: Consolidated Statement of Comprehensive Income
Figures in millions of US dollars. Three-month periods ended September 30.
| Financial Item | 2025 | 2026 |
|---|---|---|
| Revenue from Contracts with Customers | 69.0 | 53.9 |
| Biological Asset Fair Value Changes | 0.2 | (0.2) |
| Cost of Sales | (38.4) | (35.0) |
| Gross Profit | 30.8 | 18.8 |
| Gross Margin | 45% | 35% |
| Operating Expenses | (20.8) | (19.2) |
| Share of Profit of JV | 0.3 | 1.1 |
| Change in Agricultural Product NRV | (0.3) | 0.0 |
| Other Income / Expenses | (0.2) | 0.1 |
| Operating Profit | 9.7 | 0.9 |
| Financial Result | (11.9) | (10.4) |
| Loss Before Income Tax | (2.3) | (9.5) |
| Income Tax | (2.5) | (1.3) |
| Net Loss | (4.7) | (10.8) |
| Discontinued Operations Loss | (2.7) | – |
| Other Comprehensive Profit / Loss | (0.3) | 0.1 |
| Total Comprehensive Loss | (7.8) | (10.7) |
Statement of Financial Position – Assets
Figures in millions of US dollars.
| Assets | 30 June 2026 | 30 September 2026 |
|---|---|---|
| Cash and Cash Equivalents | 11.2 | 7.5 |
| Other Financial Assets | 1.0 | 1.2 |
| Trade Receivables – Current | 98.2 | 96.3 |
| Other Receivables – Current | 12.1 | 14.1 |
| Recoverable Income Tax | 1.4 | 1.4 |
| Inventories | 46.4 | 51.8 |
| Biological Assets | 0.6 | – |
| Assets Subject to Foreclosure | 44.4 | – |
| Total Current Assets | 215.4 | 172.3 |
| Trade Receivables – Non-current | 0.7 | 0.4 |
| Other Receivables – Non-current | 16.2 | 16.5 |
| Recoverable Income Tax | – | 0.0 |
| Deferred Tax Assets | 0.3 | 0.3 |
| Investments in Joint Ventures | 40.8 | 41.9 |
| Property, Plant and Equipment | 60.7 | 59.4 |
| Intangible Assets | 74.7 | 73.6 |
| Goodwill | 28.6 | 28.6 |
| Right of Use Asset | 11.0 | 10.4 |
| Total Non-current Assets | 232.8 | 231.1 |
| Total Assets | 448.2 | 403.4 |
Statement of Financial Position – Liabilities and Equity
| Liabilities and Equity | 30 June 2026 | 30 September 2026 |
|---|---|---|
| Trade and Other Payables – Current | 57.7 | 62.6 |
| Borrowings – Current | 47.3 | 56.1 |
| Employee Benefits and Social Security | 4.8 | 5.7 |
| Deferred Revenue and Customer Advances | 2.1 | 2.1 |
| Income Tax Payable | 4.9 | 6.0 |
| Acquisition Consideration | 0.0 | 0.0 |
| Secured Notes | 122.0 | 112.0 |
| Lease Liabilities – Current | 2.1 | 1.7 |
| Liabilities Subject to Foreclosure | 29.4 | – |
| Total Current Liabilities | 270.3 | 246.1 |
| Trade and Other Payables – Non-current | 42.0 | 38.9 |
| Borrowings – Non-current | 60.0 | 53.6 |
| Deferred Revenue and Advances | 1.4 | 1.4 |
| Joint Ventures and Associates | 1.1 | 1.1 |
| Deferred Tax Liabilities | 23.9 | 23.5 |
| Provisions | 6.3 | 6.3 |
| Acquisition Consideration | 0.4 | 0.4 |
| Lease Liabilities – Non-current | 8.8 | 8.7 |
| Total Non-current Liabilities | 143.8 | 134.0 |
| Total Liabilities | 414.2 | 380.1 |
| Total Equity | 34.1 | 23.4 |
| Total Equity and Liabilities | 448.2 | 403.4 |
Adjusted EBITDA Reconciliation
The company uses Adjusted EBITDA as a supplementary indicator of financial and operating performance. It is calculated by adjusting net profit or loss for financial income and costs, taxes, depreciation, amortisation, share-based compensation and specified non-recurring expenses.
| Reconciliation Item | 1Q26 ($M) | 1Q27 ($M) |
|---|---|---|
| Profit / (Loss) for the Period | (4.7) | (10.8) |
| Income Tax | 2.5 | 1.3 |
| Financial Results | 11.9 | 10.4 |
| Depreciation and Amortisation | 3.5 | 3.3 |
| Stock-based Compensation | – | (0.0) |
| Non-recurring and Transaction Expenses | 0.6 | 1.2 |
| Adjusted EBITDA | 13.9 | 5.3 |
Management considers Adjusted EBITDA useful as an additional measure of underlying operating performance. However, it is not an IFRS financial measure and should not be viewed independently of the company’s reported financial statements.
Forward-Looking Statements
This announcement contains forward-looking statements under the safe-harbour provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may be identified through terms including forecast, target, anticipate, believe, expect, estimate, plan, outlook and project.
These statements cover anticipated financial performance, operating results, cash generation, cost and working-capital initiatives, capital structure, liquidity, refinancing activities, liability management, ongoing legal proceedings and the expected performance of continuing business operations.
Forward-looking statements are based on management’s current assumptions, expectations and projections. They involve risks, uncertainties and other factors that could cause actual results to differ materially from anticipated outcomes.
The company makes no guarantee that its expectations or strategic objectives will be achieved. Investors should review the risk factors described in the company’s filings with the United States Securities and Exchange Commission.
Forward-looking statements speak only as of the date on which they are made. The company does not undertake to update them for subsequent developments or unexpected events except where required by law.
Use of Non-IFRS Financial Information
Bioceres supplements its IFRS financial reporting with certain non-IFRS measures. These measures provide additional information for management and investors but are not substitutes for IFRS results.
Non-IFRS indicators may differ from similarly named measures used by other companies, limiting direct comparisons. Management uses these indicators to assess operating performance and support financial and operational decisions.
Adjusted EBITDA does not reflect working-capital requirements, interest payments, principal repayments, income taxes, future asset replacement costs or the potential dilution from share-based compensation. Its limitations should therefore be considered alongside the company’s IFRS financial statements and reconciliations.
The company believes that presenting these measures alongside IFRS results offers additional insight into operating trends, provided that they are not considered in isolation.
About Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) develops and commercialises agricultural productivity solutions designed to regenerate agricultural ecosystems and improve the resilience of crops to climate change.
Its solutions aim to create economic incentives for farmers and other agricultural stakeholders to adopt more environmentally friendly production practices.
The company’s business activities include agricultural technologies, crop protection, seed and integrated products, crop nutrition and biological solutions.
For additional information, visit the company’s official website: Bioceres Crop Solutions .
Investor Relations Contact
Paula Savanti
Head of Investor Relations
Email:
investorrelations@biocerescrops.com
Source: Bioceres Crop Solutions Corp. | Fiscal First Quarter 2027 Financial and Operational Results | November 11, 2026.
Leave a Reply